



HAL
open science

Characterization of the GABRB2 -Associated Neurodevelopmental Disorders

Christelle Achkar, Merle Harrer, Lacey Smith, Mckenna Kelly, Sumaiya Iqbal,
Snezana Maljevic, Cristina Niturad, Lisenka Vissers, Annapurna Poduri,
Edward Yang, et al.

► **To cite this version:**

Christelle Achkar, Merle Harrer, Lacey Smith, Mckenna Kelly, Sumaiya Iqbal, et al.. Characterization of the GABRB2 -Associated Neurodevelopmental Disorders. *Annals of Neurology*, 2021, 89 (3), pp.573-586. 10.1002/ana.25985 . hal-03272477

HAL Id: hal-03272477

<https://hal.science/hal-03272477>

Submitted on 28 Jun 2021

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Characterization of the *GABRB2*-Associated Neurodevelopmental Disorders

Christelle M. el Achkar, MD,^{1,2†} Merle Harrer, MSc,^{3†} Lacey Smith, MS, CGC,¹
McKenna Kelly, BA,^{1,4} Sumaiya Iqbal, PhD,⁵ Snezana Maljevic, PhD,^{3,6}
Cristina E. Niturad, PhD,³ Lisenka E. L. M. Vissers, PhD,⁷ Annapurna Poduri, MD, MPH,^{1,2}
Edward Yang, MD, PhD,⁸ Dennis Lal, PhD,⁹ Holger Lerche, MD,^{3#}
Rikke S. Møller, PhD,^{10,11} Heather E. Olson, MD, MS,^{1,2}
and for the *GABRB2* Working Group

Objective: We aimed to characterize the phenotypic spectrum and functional consequences associated with variants in the gene *GABRB2*, coding for the γ -aminobutyric acid type A (GABA_A) receptor subunit β 2.

Methods: We recruited and systematically evaluated 25 individuals with variants in *GABRB2*, 17 of whom are newly described and 8 previously reported with additional clinical data. Functional analysis was performed using a *Xenopus laevis* oocyte model system.

Results: Our cohort of 25 individuals from 22 families with variants in *GABRB2* demonstrated a range of epilepsy phenotypes from genetic generalized epilepsy to developmental and epileptic encephalopathy. Fifty-eight percent of individuals had pharmacoresistant epilepsy; response to medications targeting the GABAergic pathway was inconsistent. Developmental disability (present in 84%) ranged from mild intellectual disability to severe global disability; movement disorders (present in 44%) included choreoathetosis, dystonia, and ataxia. Disease-associated variants cluster in the extracellular N-terminus and transmembrane domains 1–3, with more severe phenotypes seen in association with variants in transmembrane domains 1 and 2 and the allosteric binding site between transmembrane domains 2 and 3. Functional analysis of 4 variants in transmembrane domains 1 or 2 (p.Ile246Thr, p.Pro252Leu, p.Ile288Ser, p.Val282Ala) revealed strongly reduced amplitudes of GABA-evoked anionic currents.

Interpretation: *GABRB2*-related epilepsy ranges broadly in severity from genetic generalized epilepsy to developmental and epileptic encephalopathies. Developmental disability and movement disorder are key features. The phenotypic spectrum is comparable to other GABA_A receptor-encoding genes. Phenotypic severity varies by protein domain. Experimental evidence supports loss of GABAergic inhibition as the mechanism underlying *GABRB2*-associated neurodevelopmental disorders.

Address correspondence to Dr Olson, Boston Children's Hospital, 300 Longwood Ave, Mailstop 3063, Boston, MA 02115. E-mail: heather.olson@childrens.harvard.edu

[†]C.M.e.A. and M.H. are co-first authors.

[#]H.L., R.S.M., and H.E.O. are co-senior authors.

From the ¹Division of Epilepsy and Clinical Neurophysiology and Epilepsy Genetics Program, Department of Neurology, Boston Children's Hospital, Boston, MA; ²Department of Neurology, Harvard Medical School, Boston, MA; ³Department of Neurology and Epileptology, Hertie Institute for Clinical Brain Research, University of Tübingen, Tübingen, Germany; ⁴Dartmouth Geisel School of Medicine, Hanover, NH; ⁵Center for Development of Therapeutics and Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA; ⁶Florey Institute of Neuroscience and Mental Health, University of Melbourne, Melbourne, Australia; ⁷Department of Human Genetics, Donders Institute for Brain, Cognition, and Behavior, Radboud University Medical Center, Nijmegen, the Netherlands; ⁸Department of Radiology, Boston Children's Hospital, Boston, MA; ⁹Cleveland Clinic Genomic Medicine Institute and Neurological Institute, Cleveland, OH; ¹⁰Department of Epilepsy Genetics and Personalized Treatment, Danish Epilepsy Center Filadelfia, Dianalund, Denmark; and ¹¹Department of Regional Health Research, University of Southern Denmark, Odense, Denmark

Variants in γ -aminobutyric acid type A (GABA_A) receptor subunits (including *GABRA1*, *GABRB1*, *GABRB3*, and *GABRG2*) are well-established causes of epilepsy and neurodevelopmental disorders.^{1–10} The associated neurologic phenotype ranges from genetic generalized epilepsies, including absence and myoclonic epilepsies and genetic generalized epilepsy (GGE) with febrile seizures plus, to severe developmental and epileptic encephalopathies (DEE), such as Ohtahara syndrome, infantile spasms (IS), Dravet syndrome, and Lennox–Gastaut syndrome (LGS).^{1,2,5,7,8,11–21}

GABA receptors are comprised of a pentamer of subunits that form an anionic ligand-gated channel, including a combination of 2 α -subunits, 2 β -subunits, and 1 γ - or δ -subunit.²² The subtype composition varies by brain region, cell type, timing of development, and neurotrophic factors, but the most common GABA_A receptor composition is $2\alpha_1/2\beta_2/1\gamma_2$.²³ Rodent data suggest that both β_2 - and β_3 -subunits are expressed during development, that the expression of β_3 declines postnatally, and that β_2 increases during development and is highly expressed in adult brain.^{4,24,25} Given the established role of *GABRB3* in disease,^{7,8,19} we hypothesized that *GABRB2* variants cause a similar range of neurodevelopmental disease with a prominent epilepsy phenotype. In so doing, we present evidence for a strong association between *GABRB2* and neurodevelopmental disease.

Prior literature describes individuals or families with variants in *GABRB2*, presented as single reports or individuals within studies focusing on gene discovery.^{4,26–35} A recent clinical series of 15 patients with *GABRB2* variants summarizes a broad phenotypic spectrum and highlights more severe phenotypes associated with variants in the transmembrane domains.³⁴ The associated phenotypes range from febrile seizures and GGE to early onset DEE with severe neurodevelopmental handicaps and variable associated symptoms.^{4,26–30,34–36} Functional analysis of one *GABRB2* variant associated with early myoclonic encephalopathy showed abnormal trafficking of β_2 - and γ_2 -subunits.³¹ We sought to characterize the phenotypic spectrum of individuals with variants in the gene *GABRB2* by evaluating cases in an international collaboration and to evaluate functional characteristics for a subset of variants in a cell-based model.

Materials and Methods

Clinical Ascertainment

Individuals with variants in the gene *GABRB2* and neurologic disease were recruited for clinical and functional characterization. Recruitment mechanisms included the following: (1) patients seen through our Epilepsy Genetics Program at Boston

Children's Hospital; (2) families who contacted the Epilepsy Genetics Research Program at Boston Children's Hospital with interest in enrollment; (3) contact with clinicians of patients with variants in the gene *GABRB2* identified by the referring clinical laboratory GeneDx or through GeneMatcher³⁷; and (4) individuals recruited through a direct collaboration between centers in the USA, Europe, and South America. Our cohort included 17 novel individuals and 8 individuals from 6 families for whom additional clinical information was available.^{26–29,33} This study was approved by the Boston Children's Hospital Institutional Review Board (IRB), and data shared from other centers were collected with approval from local IRBs.

Literature Search

To identify cases in the literature, a PubMed search was conducted, using the terms “GABR*”, “GABRB2”, and “GABA_A”, last updated October 1, 2020. All cases including case reports, case series, and large genetic series with variants in *GABRB2* and seizures or developmental delay were reviewed.

Phenotypic Analysis

Data were collected through a combination of direct patient evaluation, detailed review of medical records, and a standardized phone interview with the subset of families enrolled through the Epilepsy Genetics Program at Boston Children's Hospital (n = 9). Thorough clinical and neurodevelopmental history, epilepsy phenotype, imaging, and metabolic and genetic testing were reviewed and collected using a standardized data collection form across centers (n = 25). Primary magnetic resonance imaging (MRI) and electroencephalographic (EEG) data were reviewed by the primary study team for a subset of individuals (n = 7). Imaging was systematically reviewed for 6 individuals by a neuroradiologist (E.Y.), and EEGs were reviewed for 6 individuals by 2 epileptologists (H.E.O., C.M.e.A.; Table S5). We defined individuals as having DEE when there was a combination of infantile/childhood onset epilepsy with an encephalopathy pattern on EEG and developmental delay or intellectual disability (ID) with both epileptic and nonepileptic factors thought to contribute to the developmental disorder.³⁸ Included encephalopathy patterns comprised burst suppression, hypersarrhythmia, electrical status epilepticus of sleep (ESES), and generalized slowing with focal or generalized epileptiform activity. Medication-refractory epilepsy was defined as not responsive to 2 or more tolerated and appropriately chosen antiseizure medications at therapeutic doses.³⁹ Epilepsy syndromes were as defined by the International League against Epilepsy (www.epilepsydiagnosis.org).³⁸

Genotypic Analysis

The genetic findings were obtained through targeted epilepsy panels (n = 3), whole exome sequencing (n = 19), or Sanger sequencing (n = 3, Family 2, Individuals 21a–c). Variant classification was performed using the most recent American College of Medical Genetics and Genomics criteria.⁴⁰ All variants are reported based on transcript NM_021911.2. We include scores

from in silico prediction models SIFT, PolyPhen-2, and CADD. We excluded variants of uncertain significance.

Functional Analysis

Functional analysis was performed as described previously.²⁹

Mutagenesis and RNA Preparation. The Quick Change kit (Stratagene, San Diego, CA) was used for mutagenesis of the *GABRB2* cDNA (pcDNA3vector). cRNA was prepared using the T7 RNA polymerase kit (Roche, Basel, Switzerland). Primers are available upon request.

Oocyte Preparation and Injection. Oocytes were obtained from the Institute of Physiology I, Tübingen, or purchased from EcoCyte Bioscience (Castrop-Rauxel, Germany). Experiments were approved by local authorities (Regierungspraesidium Tübingen, Tübingen, Germany). The preparation of oocytes for 2-microelectrode voltage clamp recordings included treatment with collagenase (1mg/ml of type CLS II collagenase; Biochrom, Berlin, Germany) in OR-2 solution (in mM: 82.5 NaCl, 2.5 KCl, 1 MgCl₂, and 5 Hepes, pH 7.6), followed by thorough washing and storing at 16°C in Barth solution (in mM: 88 NaCl, 2.4 NaHCO₃, 1 KCl, 0.41 CaCl₂, 0.82 MgSO₄, and 5 Tris/HCl, pH 7.4 with NaOH) supplemented with 50µg/ml gentamicin (Biochrom) as described previously.²⁹ Seventy nanoliters encoding the wild-type (WT) or mutant cDNA (2µg/µl) was injected into oocytes using Robooinject (Multi Channel Systems, Reutlingen, Germany). Oocytes were stored for 1 to 3 days (at 17°C) before the experiment. The combination of the different subunits used was $\alpha_1\beta_2\gamma_2s$ in a 1:1:2 ratio.

Automated Oocyte 2-Microelectrode Voltage Clamp. GABA-evoked ionic currents in oocytes were recorded at a holding potential of -70mV at room temperature (20–22°C) using GABA concentrations from 1 to 1,000µM and Roboocyte2 (Multi Channel Systems). Prepulled and prepositioned intracellular glass microelectrodes had a resistance of 0.3 to 1MΩ when filled with 1M KCl/1.5M KAc. The extracellular solution was ND96 (in mM: 93.5 NaCl, 2 KCl, 1.8 CaCl₂, 2 MgCl₂, and 5 Hepes, pH 7.5). Currents were sampled at 1kHz.

Electrophysiological Data Analysis. Amplitudes of GABA-induced currents were analyzed using Clampfit (pClamp 8.2, Axon Instruments, Union City, CA), Microsoft Excel (Microsoft, Redmond, WA), and Prism (GraphPad Software, San Diego, CA) software. The current response of each GABA concentration was normalized to the maximum response evoked by the highest GABA concentration (1mM). Current amplitudes in response to 1mM GABA application for WT and mutant channels were

recorded on the same day using the same batch of oocytes, and normalized to the mean value of WT response on the respective day. Normalized data were then pooled from different days.

A 4-parameter logistic equation was fit to the normalized GABA responses of each cell:

$$Y = \min + \frac{(\max - \min)}{1 + 10^{((\text{LogEC}_{50} - X) * nH)}}$$

with *max* and *min* being the maximum and minimum evoked responses and *X* the corresponding GABA concentration. The EC₅₀ value is the concentration of the agonist at which one-half of the maximum response is achieved, whereas *nH* is the Hill coefficient. EC₅₀ values were determined for each oocyte, and averaged values are presented as mean ± standard error of the mean (SEM).

Statistical Analysis

For statistical evaluation of functional data, GraphPad Prism 6 was used. Normalized current amplitudes were compared between different groups (WT and different variants) using 1-way analysis of variance on ranks (Kruskal–Wallis rank sum test) with Dunn post hoc test. For descriptive statistical analysis of clinical data, SAS version 9.4 was used (SAS Institute, Cary, NC).

Results

Clinical Features

We report a cohort of 25 individuals (15 male, 10 female), from 22 unrelated families, with variants in the gene *GABRB2* identified in children and adults referred for evaluation of epilepsy, movement disorder, or other neurodevelopmental disorders (Table 1). The median age at last evaluation was 8 years (range = 2–62 years). Three individuals were deceased, 1 of respiratory failure in the setting of pneumonia (#6), 1 of probable sudden unexpected death in epilepsy (#9), and 1 of respiratory failure in the setting of status epilepticus (#15). We describe the clinical findings in 17 newly reported individuals and additional data from 8 individuals in 6 families who were reported previously as part of genetic studies and on whom additional information became available.^{26–29,33}

All 25 individuals reported here harbored *GABRB2* missense variants, classified as pathogenic (*n* = 5 in 10 individuals) or likely pathogenic (*n* = 15 in 15 individuals; see Tables 1, 2, Fig 1). All variants were absent from population databases (gnomAD, <http://gnomad.broadinstitute.org/>, search updated after January 2020).⁴¹ One variant was present with apparent mosaicism (allele fraction was not specified by the clinical laboratory). All variants either occurred de novo or segregated with

TABLE 1. Summary of Key Genetic and Phenotypic Characteristics of 25 Individuals with Variants in *GABRB2*

Protein Domain	ID	Sex/ Age, yr	Variant, Classification, Domain	Age at Seizure Onset	Epilepsy Type	Encephalopathy on EEG	MD	DD	Microcephaly
Extracellular 1	1	F/19	Ala159Ser, LP	12 mo	Fo + G	N	N	Y, mild	N
	2	F/8	Met161Leu, LP	9 mo	Fo	N	N	Y, mild	N
	3	M/8	Tyr181Phe, LP	8 mo	Fo + G	N	N	Y, mild	N
	4 (28)	M/5	Tyr183His, LP	6 mo	Fo + G	N	Y	Y, mild	N
Helical 1	5	F/10	Phe245Leu, LP	3 mo	Fo + G	Y	N	Y, moderate	N
	6	M/2 ^a	Ile246Thr, P	5 mo	Fo + G	Y	N	Y, severe	Y (A)
	7	M/3	Ile246Thr, P	2 mo	Fo + G	Y	Y	Y, severe	N
	8 (26)	M/17	Pro252Ala, LP	16 yr	Fo + G	Y	N	Y, moderate	N
	9	M/6 ^a	Pro252Leu, LP	2 mo	G	Y	Y	Y, moderate	Y (A)
	10	M/3	Leu255Val, LP	5 mo	G	Y	Y	Y, moderate	N
Helical 2	11 (33)	F/16	Val282Ala, LP	3 yr	G	Y	Y	Y, moderate	Y (A)
	12 (33)	M/14	Ile288Ser, LP	15 mo	Fo + G	Y	Y	Y, severe	Y (C)
	13	F/3	Ile288Thr, LP ^b	4 mo	N/A	N	Y	Y, moderate	Y (U)
Loop M2-M3 + Allosteric Binding	14a	F/21	Arg293Trp, P ^c	13 mo	U	N	N	Y, mild	N
	14b	M/31	Arg293Trp, P ^c	18 yr	Fo	N	N	N	U
	15	F/4 ^a	Ile299Leu, LP	19 mo	Fo + G	Y	Y	Y, severe	Y (U)
	16	M/3	Ile299Ser, LP	3 mo	Fo + G	Y	Y	Y, severe	Y (A)
	17	F/4	Pro300Leu, LP	5 mo	Fo + G	N	N	Y, moderate	N
	18	M/10	Val302Met, P	8 mo	Fo + G	Y	Y	Y, moderate	Macro
	19	M/5	Lys303Arg, P	3 days	Fo + G	Y	N	Y, severe	Y (A)
	20	F/14	Ala304Thr, LP	3 yr	Fo + G	Y	Y	Y, moderate	N
Helical 3	21a (29)	M/62	Val316Ile, P ^d	11 yr	G	N	N	N	N
	21b (29)	M/37	Val316Ile, P ^d	8 yr	G	N	N	N	N
	21c (29)	M/21	Val316Ile, P ^d	9 yr	G	N	N	N	N
	22 (27)	F/4	Val316Ile, P	12 mo	Fo + G	N	N	Y, mild	N

^aIndicates age at death, from respiratory failure in the setting of pneumonia, reported sudden unexpected death in epilepsy, and status epilepticus with respiratory failure in Individuals 6, 9, and 15, respectively.

^bVariant is mosaic in the patient.

^cFamily 1.

^dFamily 2.

A = acquired; C = congenital; DD = developmental disorder; EEG = electroencephalogram; F = female; Fo = focal; G = generalized; LP = likely pathogenic; M = male; MD = movement disorder; N = no; N/A =; P = pathogenic; U = unknown; Y = yes.




FIGURE 1: Location of *GABRB2* variants in our cohort, from the literature, and in control populations. (A) Variant location in individuals reported in this study (red text) and from the literature in a 2-dimensional model of the *GABRB2* protein. Red spheres: single cases; red triangles: recurrent variants. (B) Location of missense variants in affected individuals (red spheres) and normal controls from gnomAD (blue spheres) mapped on the experimentally solved model of human $\beta 2$ -subunit (Protein Data Bank [PDB] ID: 6D6T, chain A and C).⁴⁸ Disease-associated variants are in regions lacking variation in controls. (C) Disease-associated variant locations (red spheres) by $\beta 2$ -subunit protein domain (PDB ID: 6D6T, chain A and C). The extracellular and helical transmembrane domains are highlighted in purple and green, respectively. Two functionally critical regions, the agonist binding region (yellow, harbors the patient variant: p.Tyr181Phe) and the allosteric effector binding region (pink, contains 12 patient variants) are also shown in the structure. (D) *GABRB2* tolerance landscape using MetaDome.⁴⁹ Functional domains are highlighted in purple. Vertical green lines in the schematic representation of the *GABRB2* protein indicate the locations where (likely) pathogenic missense variants were observed. From this visualization, it can be concluded that all missense variants locate to regions of *GABRB2* that are intolerant to functional variation.

phenotype in 2 families (see Table 2). One variant was inherited in a family with affected father and daughter (p.Arg293Trp). The p.Val316Ile variant was present in 1 individual as a de novo variant and was also present in an affected family.

Missense variants were located in regions of the protein that are intolerant to functional variation (see Fig 1C). The 20 unique variants occurred at 17 different amino acid positions. Thirteen amino acid positions were associated with the same recurrent or different missense

TABLE 2. Genetic Details for Variants in GABRB2 Identified in 25 Individuals from 22 Families

ID	cDNA	Protein	Inh.	Test	SIFT	P2	CS	ACMG Classification ⁴⁰
1	475G > T	A159S	De novo	WES ^a	0.139	0.40	23.7	LP: PM2, PM2, PP2, BP4
2	481A > C	M161L	De novo	Panel ^b	0.009	0.76	26.1	LP: PM2, PM6, PP2, PP3
3	542A > T	Y181F	De novo	Trio WES	0.003	0.73	28.5	LP: PM2, PM6, PP2, PP3
4 ²⁸	547 T > C	Y183H	De novo	Trio WES	0.000	1.00	28.3	LP: PS2, PM2, PP2, PP3
5	735 T > A	F245L	De novo	Trio WES	0.002	0.99	24.8	LP: PS2, PM2, PP2, PP3
6	737 T > C	I246T	De novo	Trio WES	0.046	0.92	27.1	P: PVS, PM2, PP2, PP3
7	737 T > C	I246T	De novo	Trio WES	0.046	0.92	27.1	P: PVS, PM2, PP2, PP3
8 ²⁶	754C > G	P252A	De novo	Trio panel ^b	0.000	1.00	26.4	LP: PS2, PM2, PP2, PP3
9	755C > T	P252L	De novo	Trio WES	0.000	1.00	25.8	LP: PS2, PM2, PM5, PP2
10	763C > G	L255V	De novo	Trio WES	0.001	0.96	23.0	LP: PS2, PM2, PP2, PP3
11 ³³	845 T > C	V282A	De novo	Trio WES	0.000	1.00	27.4	LP: PS (PS2 + PM6), PM2, PP2, PP3
12 ³³	863 T > G	I288S	De novo	Trio WES	0.000	1.00	28.1	LP: PS2, PM2, PP2, PP3
13	863 T > C	I288T	De novo ^c	Trio WES	0.000	1.00	26.5	LP: PS2, PM2, PM5, PP2
14a	877C > T	R293W	I ^d	Trio WES	0.000	1.00	28.2	P: PS1, PS3, PM2
14b	877C > T	R293W	U ^d	Trio WES	0.000	1.00	28.2	P: PS1, PS3, PM2
15	895A > C	I299L	De novo	Trio WES	0.000	0.76	26.2	LP: PM2, PM6, PP2, PP3
16	896 T > G	I299S	De novo	Panel ^c	0.000	1.00	28.8	LP: PM2, PM6, PP2, PP3
17	899C > T	P300L	De novo	Trio WES	0.002	0.99	29.5	LP: PM2, PM6, PP2, PP3
18	904G > A	V302M	De novo	Trio WES	0.001	0.99	28.3	P: PS1, PS2, PM2, PP2
19	908A > G	K303R	De novo	Trio WES	0.000	1.00	27.5	P: PS1, PS2, PM2, PP
20	910G > A	A304T	De novo	Trio WES	0.001	1.00	28.8	LP: PS1, PM2, PM6, PP2
21a ²⁹	946G > A	V316I	U ^e	SS	0.032	1.00	24.7	P: PS1, PS3, PM2, PP1
21b ²⁹	946G > A	V316I	I ^e	SS	0.032	1.00	24.7	P: PS1, PS3, PM2, PP1
21c ²⁹	946G > A	V316I	I ^e	SS	0.032	1.00	24.7	P: PS1, PS3, PM2, PP1
22 ²⁷	946G > A	Va316I	De novo	WES ^a	0.032	1.00	24.7	P: PS1, PS3, PM2, PP1

Genetic variants all use reference transcript NM_021911.2.

^aSingleton test.

^bNext generation sequencing panel.

^cMosaic.

^dFamily 1.

^eFamily 2.

ACMG = American College of Medical Genetics and Genomics; CS = CADD score; I = inherited; Inh. = inheritance; LP = likely pathogenic; P = pathogenic; P2 = PolyPhen-2; SS = Sanger sequencing; U = unknown; WES = whole exome sequencing.

variants in 2 or more unrelated individuals in this series or overlapping with reported literature within the N-terminal, transmembrane domains and the extracellular loop between M2 and M3 (see Fig 1,).

Epilepsy was diagnosed in 24 of 25 individuals (96.0%): 6 generalized, 2 focal, 15 combined, and 1 of unknown type (see Table 1). Median age at onset was 9 months, with a range from 3 days to 18 years, including 15 with onset before age 1 year. Of 13 individuals with DEE, median age at seizure onset was 5 months (range = 3 days–16 years), all with early developmental disabilities. Generalized seizure types included generalized tonic–clonic (GTC), tonic, spasms, myoclonic, atonic, and typical and atypical absence (). Focal seizure types included motor (focal tonic, focal clonic, focal myoclonic) and nonmotor. GTC seizures with focal or generalized onset occurred in at least 17 of 24 individuals with epilepsy (70.8%). Spasms were seen in 2 individuals and myoclonic seizures (focal or generalized) in 6. Typical absence seizures were reported in 5 individuals, including 3 from a single family with GGE (p.Val316Ile, Individuals 22–24),²⁹ and atypical absence seizures were reported in an additional 3 individuals. Fever sensitivity, defined as a frequent trigger for seizures, was reported in 12 of 24 individuals (50.0%). Eleven of 24 individuals with epilepsy (45.8%) had at least 1 episode of status epilepticus, including convulsive and nonconvulsive types.

Syndrome classification included early onset epileptic encephalopathy with burst suppression, including early myoclonic encephalopathy in 2 individuals, early onset infantile spasms in 2, febrile seizures plus or Dravet-like in 3, Lennox–Gastaut-like syndrome in 3, epileptic encephalopathy with continuous spike wave in slow-wave sleep (CSWS) in 1,¹ and temporal lobe epilepsy¹ (see Table S2).

Epilepsy was medically refractory in 13 of 24 (54.1%) individuals. Seizure frequency was daily in at least 8 of 24 individuals (33.3%; Table 3).

EEGs showed epileptic encephalopathy patterns in 13 of 25 individuals (52.0%; see Table 1). These included severe early encephalopathy patterns of hypsarrhythmia and/or burst suppression in 5 individuals in the first 2 years of life, ESES in 2 individuals, and nonspecific slowing with generalized and/or multifocal sharp waves in 6 individuals (). In 12 individuals, EEG background was normal but in some cases demonstrated focal (n = 4) or generalized (n = 8) epileptiform activity. Two individuals with generalized epilepsy had a photoparoxysmal response.

Response to antiseizure medications is available in detail in Table S6. Detailed analysis did not show that antiseizure medications targeting the GABA pathway, such

as benzodiazepines, vigabatrin, and phenobarbital, were either more beneficial or harmful compared to antiseizure medications with other mechanisms. Levetiracetam and valproic acid were most commonly used but were not clearly superior to other medications in response rate. The ketogenic diet and modified Atkins diet were reported as beneficial in 3 of 4 individuals. Age at initiation and discontinuation of medications was not available in detail in most individuals.

Developmental disability was reported in 21 of 25 individuals (84.0%; see Table 1), of whom all except 1 had confirmed epilepsy. Of these, 6 were severely impaired, with lack of head control and predominantly nonspecific vocalizations. Nine were moderately to severely globally impaired, and 6 had mild neurodevelopmental delays, ID, or learning disability (). Severity was determined based on best attained milestones and cognitive level. Those individuals who were most severely impaired developmentally additionally had severe epilepsy. Age at seizure onset was also associated with severity of developmental impairment (median = 5 months, interquartile range [IQR] = 3 months–1.6 years) for those with moderate to severe developmental impairment compared to 1 year (IQR = 9 months–9 years) for those with normal development or mild impairment (Wilcoxon rank sum test $p = 0.03$). Five (20.0%) had reported developmental regression that occurred during infancy in 2 individuals, occurred in the setting of severe movement disorder requiring prolonged hospitalization at age 3 years in 1 individual, and consisted of language regression at school age in the other 2 individuals. One of the individuals with language regression at school age had periodic improvement and decline in developmental skills with associated behavioral changes and sleep disturbance, unrelated to epileptic encephalopathy (# 5). Four individuals (16.0%) had a normal developmental profile. The behavioral and psychiatric profile consisted of 5 individuals with a notable social/happy personality, 5 with attention-deficit/hyperactivity disorder or hyperactivity, 3 with anxiety, 2 with obsessive–compulsive disorder, 2 with aggressive behavior, 1 with delusions, and 1 with hallucinations and ritualistic behaviors. Seven individuals (28.0%) had autistic features, including poor eye contact, motor stereotypies, repetitive behaviors, and ritualistic behaviors. Cortical visual impairment was reported in 8 of 25 individuals (32.0%).

Movement disorders were reported in 11 individuals (44.0%), including chorea or choreoathetosis in 8, dystonia in 3, ataxia in 3, hyperkinesia in 2, not otherwise specified dyskinesias in 2, tremors in 1, nonepileptic myoclonus in 1, and forced paroxysmal downgaze in 1

TABLE 3. Additional Neurologic Characteristics for 25 Individuals with *GABRB2* Variants

ID	Intractable Epilepsy	SE	Epilepsy Syndrome	CVI	Cognitive Impairment	Movement Disorder and Type
1	No	Yes	Dravet-like	No	IDis, mild	No
2	No	No	FS+	No	LD	No
3	Yes	Yes	Dravet-like	No	U	No
4	Yes	Yes	No	U	IDis, mild	Ataxia, asymmetric
5	No	No	No	No	IDis, unspecified	No
6	Yes	Yes	LGS-like	Yes	U	No
7	Yes	No	EME	Yes	IDis, severe	Severe dystonia
8	No	No	CSWS	Yes	IDis, severe	No
9	Yes	Yes	EOEE, IS, LGS-like	Yes	IDis, severe	Choreoathetosis, dystonia, dyskinesias
10	Yes	No	No	Yes	U	Choreoathetosis, dystonia, tremors, opsoclonuslike eye movements, paroxysmal downgaze
11	No	No	No	Yes	U	Chorea
12	Yes	Yes	LGS-like	Yes	IDis, unspecified	Chorea
13	U	U	No	U	U	Hyperkinetic, chorea
14a	Yes	Yes	No	No	Borderline	No
14b	Yes	No	TLE	No	None	No
15	Yes	Yes	No	Yes	Unknown	Chorea, dyskinesias, myoclonus
16	Yes	No	IS	No	Unknown	Choreoathetosis
17	No	No	No	No	IDis, unspecified	No
18	No	Yes	No	No	IDis, unspecified	Ataxia and chorea, hyperkinetic
19	Yes	Yes	EOEE-BS	U	IDis, profound	No
20	Yes	Yes	No	U	IDis, unspecified	Ataxic gait
21a	No	No	JAE	No	None	No
21b	No	No	JAE	No	None	No
21c	No	No	CAE	No	None	No
22	No	No	No	No	None	No

CAE = childhood absence epilepsy; CSWS = continuous spike wave in slow-wave sleep; CVI = cortical visual impairment; EME = early myoclonic encephalopathy; EOEE = early onset epileptic encephalopathy; EOEE-BS = EOEE with burst suppression; FS+ = febrile seizures plus; IDis = intellectual disability; IS = infantile spasms; JAE = juvenile absence epilepsy; LD = learning disability; LGS = Lennox–Gastaut syndrome; SE = status epilepticus; TLE = temporal lobe epilepsy; U = unknown.

(see Table 3). In Individual #10, the movement disorder was the presenting symptom and the severity resulted in chronic hospitalization culminating in placement of deep brain stimulation (DBS). Thalamic DBS resulted in substantial improvement in his dystonia, choreoathetosis,

developmental progress, and seizures. Movement disorders were chronic, with onset in infancy to early childhood, in all 11 individuals. We demonstrate representative movement disorders in the supplemental videos. Diagnosis of movement disorder was more common in the presence of




FIGURE 2: Location of all disease-associated variants (red spheres) mapped on the experimentally solved model of human $\beta 2$ -subunit (Protein Data Bank ID: 6D6T, chain A and C),⁴⁸ and variants associated with electroencephalographic encephalopathy (magenta spheres), movement disorder (orange spheres), and developmental disorder (brown spheres). Spatial distributions of variants by phenotypes show that patient variants located in the extracellular domain (in the dashed box) are mostly associated with developmental delay and less often with epileptic encephalopathy or movement disorder.


an encephalopathy pattern on EEG (9 of 13, 69%, compared to 2 of 12, 17%, Fisher exact test $p = 0.02$) and moderate to severe cognitive/developmental impairment (10 of 15, 66% compared to 1 of 10, 10%, Fisher exact test $p = 0.01$). Median seizure onset was 6 months (IQR = 3 months–1.6 years) for those with movement disorder compared to 1 year (IQR = 5 months–9 years) for those without movement disorder, but the relationship does not reach statistical significance (Wilcoxon rank sum test $p = 0.2$).

On neurological examination, strabismus was reported in 8 (32.0%; Table S4). Tone was abnormal in 18 individuals (72.0%), including hypotonia (11, axial or diffuse), hypertonia (5, spasticity, rigidity, or dystonia), and mixed tone abnormalities.² Both hypotonia and hypertonia were seen in infancy, childhood, and adolescence in different patients. Tone varied with age in some individuals from hypotonia to normal tone. None developed hypotonia after having had a normal examination or hypertonicity. Reflexes were increased in 7 individuals (28.0%) in association with hypotonia, hypertonia, or mixed tone abnormalities. Two individuals had reported areflexia on physical examination. The first had hyperreflexia initially but was always described as hypotonic (#9). The second had hypertonia with no report of areflexia over time (#11). Head size was reported as normal in 15, microcephaly in 8, macrocephaly in 1 (familial), and unknown in 1 (see Table 1). Microcephaly was congenital in 1 individual and acquired in 5, and subtype was unknown in the other 2. Descriptions of mild characteristic facial and limb features not fitting a specific pattern were reported in 8 of 25 individuals (32.0%), including flat facies, up-slanting or down-slanting palpebral fissures, hypertelorism, ptosis, low set dysplastic pinnae, short

philtrum, micrognathia, high arched palate, and tapered fingers

In terms of overall outcomes, at the time of this analysis, 3 individuals had died; all 3 had had DEE with early onset seizures, refractory epilepsy, and severe developmental disability. Twelve individuals became seizure-free (including Individual #3, who was initially refractory), 3 with no developmental disabilities or cognitive impairment and 8 with mild or moderate developmental disabilities. Seizure outcome data were unavailable on 1 individual (#13). The remaining 9 had refractory epilepsy, 2 with no developmental disabilities or cognitive impairments, and 7 with a range of developmental disabilities. Movement disorders were chronic and persistent in those affected ($n = 11$), including 1 (#10) with high severity requiring DBS.

Brain MRI was reported as normal in 13 of 23 individuals for whom data were available (56.5%; see Table S5). Mild volume loss with prominent sulci and/or mild lateral ventriculomegaly indicating gray or white matter volume loss was observed in 5 individuals, and borderline low volume was seen in an additional 2; imaging from 5 of these 7 individuals was reviewed formally by our neuroradiologist. Neuroimaging was initially normal in at least 2 of the 7 individuals with gray or white matter volume loss. Other nonspecific abnormalities, each seen in a single individual, included possible cortical dysplasia, hippocampal volume loss, hippocampal inversion/under-rotation, nonspecific T2 signal change or gliosis, mild hyperintensity of the splenium of the corpus callosum, thick corpus callosum, and Chiari malformation with syrinx. Neuroimaging data were not available for 1 individual, and another had only a head computed tomography scan that was normal.



Localization of Variants in the Protein

Overall, disease-associated variants in our series and the literature are clustered in the functional core of the protein, mainly the N-terminus and transmembrane regions M2 and M3 (shown in red in Fig 1B). Population-based variants derived from the database gnomAD (gnomAD browser: <http://gnomad.broadinstitute.org/>) are distributed differently in functionally less important regions, primarily in the outer surface of the pentameric GABA_A receptor complex (shown in blue in Fig 1B). Variants in the extracellular N-terminus and in M3 were associated with a less severe phenotype including predominantly a milder neurodevelopmental disability and less often epileptic encephalopathy and movement disorder compared to variants in M1, M2, and the allosteric binding domain between M2 and M3 (see Figs 1 and 2), as confirmed by Fisher exact testing. Of 17 individuals with variants in M1, M2, or the allosteric binding domain, moderate to severe developmental disability was reported in 15 (88.2%), epileptic encephalopathy patterns were reported on EEG in 13 (76.5%), and movement disorder was reported in 10 (58.8%). In contrast, of 8 individuals with variants in the N-terminus and M3, all had normal development or mild developmental disability ($p < 0.0001$), none had an epileptic encephalopathy pattern on EEG ($p = 0.0005$), and movement disorder was reported in 1 (12.5%, $p = 0.04$).

Functional Analysis. We performed functional analysis of 4 de novo *GABRB2* variants identified in the first individuals with DEE phenotypes enrolled in this study. They are located in M1 (p.Ile246Thr, p.Pro252Leu) and M2 (p.Ile288Ser, p.Val282Ala) segments (Fig 3), all affecting

FIGURE 3: Functional analysis in *Xenopus oocytes* of 4 de novo *GABRB2* variants associated with developmental and epileptic encephalopathies. (A) Schematic representation of the β 2-subunit of the γ -aminobutyric acid type A (GABA_A) receptor showing the localization of the variants. (B) Normalized current response to 1mM GABA application for $\alpha_1\beta_2\gamma_2\delta$ wild-type (WT) receptors ($n = 27$), and receptors carrying the variants p.Val282Ala (V282A, $n = 16$), p.Pro252Leu (P252L, $n = 14$), p.Ile288Ser (I288S, $n = 10$), and p.Ile246Thr (I246T, $n = 21$) in the β 2-subunit. Shown are all data points for each oocyte and median with range * $p < 0.001$, **** $p < 0.0001$ (Kruskal-Wallis with Dunn's post-hoc test). (C) Dose-response curve for WT ($n = 10$), I246T ($n = 16$) and V282A ($n = 16$) containing receptors after application of different GABA concentrations ranging from 0.001 μ M to 1mM and normalization to the maximal GABA response for each cell. (D) Dose-response curve for WT ($n = 21$), p.Ile288Ser (I288S, $n = 12$) and p.Pro252Leu (P252L, $n = 14$) as in C. Shown in C and D are means \pm SEM (error bars are sometimes smaller than symbol size).**

(Figure legend continues on next column.)

conserved amino acids. Data are presented as median with range. Statistically significant differences with p values are indicated in the legend to Figure 3.

GABA-evoked ionic currents were recorded with an automated 2-microelectrode voltage clamp technique from oocytes expressing WT or mutant β_2 -subunits together with WT α_1 - and γ_2 -subunits. After application of 1mM GABA, we observed a significant reduction of amplitudes of GABA-induced anion currents for all 4 variants in comparison to the WT (see Fig 3). The GABA sensitivity of the altered receptors was studied by applying different GABA concentrations. Dose–response curves of variants p.Ile246Thr and p.Val282Ala indicated a higher GABA sensitivity upon application of very low GABA concentrations of 0.01 to 10 μ M. However, taking into account the observed reduction in current amplitude, an overall effect of these variants within the whole range of GABA applications, including synaptically relevant high concentrations, is a loss of function (see Fig 3C, dashed lines). For p.Ile288Ser and p.Pro252Leu variants, we observed no change in GABA sensitivity (see Fig 3D). The EC₅₀ values and the statistical difference in mean GABA sensitivity expressed as EC₅₀ for each variant compared to WT determined with the Kruskal–Wallis test and Dunn multiple comparison test were as follows (mean \pm SEM: WT, 80 \pm 10 μ M; p.I246T, 11 \pm 3 μ M [$p < 0.0001$]; p.V282A, 27 \pm 5 μ M [$p < 0.001$]; p.I288S, 57 \pm 6 μ M [$p > 0.99$]; p.P252L, 47 \pm 9 μ M [$p = 0.6$]).

Discussion

Through our analysis of 25 individuals and the literature, we delineate a range of neurodevelopmental phenotypes associated with *GABRB2* variants, including various epilepsy phenotypes, developmental disabilities, and movement disorders. We newly report movement disorders with onset in infancy, at times severe enough to consider DBS, and in 1 case as the presenting feature. We further describe preliminary differences in phenotypic severity based on location of variants within the protein. Functional analysis of 4 missense variants in transmembrane domains 1 and 2, all associated with severe neurological phenotypes, demonstrates a loss of function of GABA-induced anion currents.

All but 1 individual in our cohort had confirmed epilepsy, and the 1 individual without epilepsy had events that were considered suspicious for seizures. This high rate of epilepsy may represent an ascertainment bias, however, as many individuals were investigated because of their diagnosis of epilepsy. We demonstrated a wide range of epilepsy types and syndromes from GGE to DEE as well as a wide range of developmental disabilities, overlapping

closely with those reported in association with variants in other GABA_A receptor subunit genes.^{1–21} Distinct fever sensitivity is noted in one-half of our cohort, as in prior reports of GABA_A receptor subunit variation in association with syndromes including genetic epilepsy with febrile seizures plus spectrum and Dravet syndrome.^{5,7,13,17,20} A recent series also demonstrated fever sensitivity in 13 of 15 individuals.³⁴ We newly report association of age at seizure onset with severity of developmental impairment, a relationship that is not unexpected but not previously assessed by studies of GABA_A receptor-associated neurodevelopmental disorders. The effect of GABAergic medications on seizures was mixed for patients with the 2 variants associated with higher receptor sensitivity to GABA (p.Ile246Thr and p.Val282Ala; see Table S6). Retrospective assessment of treatment responses did not suggest a difference in response to antiseizure medications targeting GABA pathways compared to other mechanisms. Prior studies of epilepsy related to GABA_A receptor subunit variants did not specifically evaluate treatment response or report distinct patterns. Retrospective data collection and cohort size limit our ability to assess response to medications with regard to age or particular seizure types.

Movement disorders were observed in 44% of this cohort, including choreoathetosis, dystonia, ataxia, and tremors, and demonstrated association with encephalopathy on EEG and moderate to severe developmental impairment. Similarly, 5 of the 11 individuals reported by Hamdan et al with *GABRB2* variants (45%) had movement disorders, including incoordination, ataxia, dystonia, dyskinesia, and choreoathetosis.²⁷ Prominent infantile onset movement disorder, as seen in 5 of the 11 individuals with movement disorders in this series, were not previously described in individuals with variants in other GABA_A receptor genes. Ataxia is reported in 4 and dyskinesias in 1 of 22 individuals with *GABRB3* variants in the largest reported series and in scattered additional cases.^{2,7,32} Choreoathetosis and dystonia are reported in 2 individuals with *GABRA1* variants.¹⁴ The overlap of movement disorders and epilepsy is well described in a number of other genetic disorders, including *FOXG1*, *FRRS1L*, *GNAO1*, *PRRT2*, *SLC2A1*, *STXBP1*, and others.^{42–44} The spectrum of movement disorders seen in the setting of variants in GABA_A receptor subunit genes and phenotype–genotype correlations warrants further study. A key feature of this cohort design is that individuals were enrolled at various ages, and it is possible that the phenotypic developmental delay and movement disorders may develop or be diagnosed later for some of the individuals enrolled in this study.

Functional analysis indicates a loss-of-function mechanism for *GABRB2*, comparable to findings for

variants in *GABRB3* and other GABA_A receptor genes.^{7,10,29,45,46} Two of the variants (p.Ile246Thr and p.Val282Ala) led to a higher GABA sensitivity at low concentrations but did not impact the profound reduction of currents evoked by physiologic GABA concentrations during synaptic transmission. The suggested epileptogenic mechanism is therefore a disinhibition at GABAergic synapses, providing a target for the development of future attempts at precision medicine to treat *GABRB2*-related conditions. Reduced GABA-evoked peak current amplitudes and abnormal subunit trafficking are mechanisms identified for disease associated-variants in other GABA_A receptor β -subunit genes.^{7,45,46} Similarly, functional studies of DEE-associated de novo variants in *GABRB3* and *GABRB1* in an HEK cell model show reduced peak current amplitudes in LGS-associated variants and altered kinetics in IS-associated variants.⁴⁵

We highlight several amino acid positions with disease-associated missense changes affecting more than 1 individual in this series or the literature.^{26–28,30,32,34} Disease-associated variants, unique and recurrent, are localized in regions intolerant to functional variation (lacking variation in control populations), including portions of the extracellular domain, as well as the extracellular agonist binding region, the helical transmembrane domains near the gating and pore regions, and the allosteric effector binding region. Variants detected in controls, as provided by gnomAD, are in functionally less important regions, primarily in the outer surface of the GABA_A receptor complex (see Fig 1B). Notably, we identified only missense variants. This may reflect that truncating variants or deletions may be either better tolerated or prenatally lethal. The pLI score (probability of being loss-of-function intolerant) in gnomAD is 0.85, suggesting that *GABRB2* truncating variants or deletions are not likely to be lethal. A mouse model of missense knockin versus knockout of the γ_2 -subunit demonstrated absence seizures in both models but a severe phenotype with thermal seizure susceptibility in the γ_2 (R43Q) knockin.⁴⁷ Further study is needed to determine the impact of loss-of-function variants compared to missense variants.

Although the cohort size is small for assessment of genotype–phenotype correlations, we observed more severe phenotypes in association with variants in M1 and M2 and the allosteric binding site between M2 and M3 compared to variants in the extracellular N-terminus and M3. This finding is consistent with recent work highlighting a more severe phenotype in association with variants in the transmembrane domains.³⁴ Localization of 97 variants found in different GABA_A receptor subunit genes in monogenic epilepsies was contrasted with variants listed in gnomAD, and significant differences were found exactly in defined

and highly conserved regions of the N-terminus, M1–3, and the linker region between M2 and M3.¹⁰ Mild and severe phenotypes were not differentiated in that review. Further studies of larger cohorts are needed to validate our genotype–phenotype correlations and identify others.

Given the overall small number of individuals, variant-specific genotype–phenotype correlation is more difficult than domain-specific genotype–phenotype correlation. Some of the recurrent amino acid positions were associated with similar phenotypes (eg, 181 with Dravet and Dravet-like syndrome, 316 with GGE in 3 family members, and generalized epilepsy with mild delays in 1 unrelated individual), whereas others showed no phenotypic similarities (eg, 252 with CSWS in 1 individual and early onset epileptic encephalopathy/IS in another).

In conclusion, we delineate the epilepsy and other neurodevelopmental phenotypes associated with variants in *GABRB2*, underscoring the wide range of epilepsy and developmental phenotypes and calling attention to movement disorders as a previously unrecognized key feature. We highlight functionally important regions of the β_2 -subunit in which disease-associated variants, including some recurrent variants, are located, and note that these are distinct from regions in which there are benign polymorphisms in the general population. Finally, we demonstrate loss of function in a cellular model. We thus provide several lines of evidence to establish the role of *GABRB2* in neurodevelopmental disease. Given the different manifestations of *GABRB2*, this gene should be considered as a possible cause for patients presenting with any of the above symptoms, alone or in combination. Although we did not identify specific treatment responses to GABAergic or other classes of antiseizure medication, early genetic diagnosis and future prospective studies may better identify treatments beneficial to treat the seizures and movement disorders associated with *GABRB2* and other GABA_A receptor encoding genes. Genetic diagnosis will also be critical in the case of future disease-modifying therapy or gene-specific clinical trials.

Acknowledgments

H.E.O. was supported by the NIH National Institute of Neurologic Disorders and Stroke (K23 NS107646-02 and NINDS 5K12NS079414-02), and by the Administrative Core of Boston Children’s Hospital Intellectual and Developmental Disabilities Research Center (1U54HD090255). A.P. was supported by the Boston Children’s Hospital Translational Research Program. R.S.M. was supported by the Novo Nordisk Foundation (NNF19OC0058749). H.L. was supported by the German Research Foundation (FOR-2715, grant

LE1030/16-1). Sarah Weckhuysen of the *GABRB2* Working Group receives funding from the Research Foundation-Flanders (FKM 1861419 N), University of Antwerp (BOF-FFB180053), and the European Union H2020 program (856592). Pasquale Striano and Federico Zara of the *GABRB2* Working Group developed this work within the framework of the Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, and Maternal and Children's Sciences, Department of Excellence of the Italian Ministry of Education, University and Research 2018-2022 (legge 232 del 2016). Katalin Sterbova of the *GABRB2* Working Group is supported by Ministry of Health of the Czech Republic (AZV NU20-04-00279). Sequencing and analysis for Individual #10 was provided by the Broad Institute of Massachusetts Institute of Technology and Harvard Center for Mendelian Genomics (Broad Center for Mendelian Genomics) and was funded by the National Human Genome Research Institute, the National Eye Institute, and the National Heart, Lung, and Blood Institute (UM1 HG008900) and in part by the National Human Genome Research Institute (R01 HG009141).

We thank the individuals and families who participated in the collection of clinical data for this project and for enrolling in our research studies; and our colleagues who referred families to our center and our clinical colleagues who evaluated patients.

Author Contributions

H.L., R.S.M., and H.E.O. contributed to conception and study design. C.M.e.A., M.H., L.S., S.I., S.M., C.E.N., L.E.L.M.V., E.Y., D.L., R.S.M., and H.E.O. contributed to drafting the text or preparing the figures.

Potential Conflicts of Interest

Erin Torti and Fanggeng Zou of the *GABRB2* Working Group are employees of GeneDx, which is a referring clinical laboratory for this study. The remaining authors have nothing to report.

References

- Baulac S, Huberfeld G, Gourfinkel-An I, et al. First genetic evidence of GABA(a) receptor dysfunction in epilepsy: a mutation in the gamma2-subunit gene. *Nat Genet* 2001;28:46–48.
- Burgess R, Wang S, McTague A, et al. The genetic landscape of epilepsy of infancy with migrating focal seizures. *Ann Neurol* 2019;86:821–831.
- Epi4K Consortium, Epilepsy Phenome/Genome Project, Allen AS, et al. De novo mutations in epileptic encephalopathies. *Nature* 2013;501:217–221.
- Hirose S. Mutant GABA(a) receptor subunits in genetic (idiopathic) epilepsy. *Prog Brain Res* 2014;213:55–85.
- Kang JQ, Macdonald RL. Molecular pathogenic basis for GABRG2 mutations associated with a spectrum of epilepsy syndromes, from generalized absence epilepsy to Dravet syndrome. *JAMA Neurol* 2016;73:1009–1016.
- Macdonald RL, Kang JQ, Gallagher MJ. In: Noebels JL, Avoli M, Rogawski MA, et al., eds. *GABAA receptor subunit mutations and genetic epilepsies*. Bethesda, MD: National Institutes of Health: Jasper's basic mechanisms of the epilepsies, 2012:714–749.
- Moller RS, Wuttke TV, Helbig I, et al. Mutations in GABRB3: from febrile seizures to epileptic encephalopathies. *Neurology* 2017;88:483–492.
- Papandreou A, McTague A, Trump N, et al. GABRB3 mutations: a new and emerging cause of early infantile epileptic encephalopathy. *Dev Med Child Neurol* 2016;58:416–420.
- Rochtus A, Olson HE, Smith L, et al. Genetic diagnoses in epilepsy: the impact of dynamic exome analysis in a pediatric cohort. *Epilepsia* 2020;61:249–258.
- Maljevic S, Moller RS, Reid CA, et al. Spectrum of GABAA receptor variants in epilepsy. *Curr Opin Neurol* 2019;32:183–190.
- Dibbens LM, Feng HJ, Richards MC, et al. GABRD encoding a protein for extra- or peri-synaptic GABAA receptors is a susceptibility locus for generalized epilepsies. *Hum Mol Genet* 2004;13:1315–1319.
- Dibbens LM, Harkin LA, Richards M, et al. The role of neuronal GABA(a) receptor subunit mutations in idiopathic generalized epilepsies. *Neurosci Lett* 2009;453:162–165.
- Johnston AJ, Kang JQ, Shen W, et al. A novel GABRG2 mutation, p. R136*, in a family with GEFS+ and extended phenotypes. *Neurobiol Dis* 2014;64:131–141.
- Kodera H, Ohba C, Kato M, et al. De novo GABRA1 mutations in Ohtahara and West syndromes. *Epilepsia* 2016;57:566–573.
- Lachance-Touchette P, Brown P, Meloche C, et al. Novel alpha1 and gamma2 GABAA receptor subunit mutations in families with idiopathic generalized epilepsy. *Eur J Neurosci* 2011;34:237–249.
- Maljevic S, Krampfl K, Cobilanschi J, et al. A mutation in the GABA(a) receptor alpha(1)-subunit is associated with absence epilepsy. *Ann Neurol* 2006;59:983–987.
- Sun H, Zhang Y, Liang J, et al. SCN1A, SCN1B, and GABRG2 gene mutation analysis in Chinese families with generalized epilepsy with febrile seizures plus. *J Hum Genet* 2008;53:769–774.
- Tian M, Mei D, Freri E, et al. Impaired surface alphabeta gamma GABA(a) receptor expression in familial epilepsy due to a GABRG2 frameshift mutation. *Neurobiol Dis* 2013;50:135–141.
- Urak L, Feucht M, Fathi N, et al. A GABRB3 promoter haplotype associated with childhood absence epilepsy impairs transcriptional activity. *Hum Mol Genet* 2006;15:2533–2541.
- Carvill GL, Weckhuysen S, McMahon JM, et al. GABRA1 and STXPB1: novel genetic causes of Dravet syndrome. *Neurology* 2014;82:1245–1253.
- Tanaka M, Olsen RW, Medina MT, et al. Hyperglycosylation and reduced GABA currents of mutated GABRB3 polypeptide in remitting childhood absence epilepsy. *Am J Hum Genet* 2008;82:1249–1261.
- Baumann SW, Baur R, Sigel E. Forced subunit assembly in alpha1beta2gamma2 GABAA receptors. Insight into the absolute arrangement. *J Biol Chem* 2002;277:46020–46025.
- Grabenstatter HL, Russek SJ, Brooks-Kayal AR. Molecular pathways controlling inhibitory receptor expression. *Epilepsia* 2012;53(71–78).
- Brooks-Kayal AR, Pritchett DB. Developmental changes in human gamma-aminobutyric acid receptor subunit composition. *Ann Neurol* 1993;34:687–693.

25. Laurie DJ, Seeburg PH, Wisden W. The distribution of 13 GABAA receptor subunit mRNAs in the rat brain. II. Olfactory bulb and cerebellum. *J Neurosci* 1992;12:1063–1076.
26. Bosch DG, Boonstra FN, de Leeuw N, et al. Novel genetic causes for cerebral visual impairment. *Eur J Hum Genet* 2016;24:660–665.
27. Hamdan FF, Myers CT, Cossette P, et al. High rate of recurrent De novo mutations in developmental and epileptic encephalopathies. *Am J Hum Genet* 2017;101:664–685.
28. Heyne HO, Singh T, Stamberger H, et al. De novo variants in neurodevelopmental disorders with epilepsy. *Nat Genet* 2018;50:1048–1053.
29. May P, Girard S, Harrer M, et al. Rare coding variants in genes encoding GABAA receptors in genetic generalised epilepsies: an exome-based case-control study. *Lancet Neurol* 2018;17:699–708.
30. Srivastava S, Cohen J, Pevsner J, et al. A novel variant in *GABRB2* associated with intellectual disability and epilepsy. *Am J Med Genet A* 2014;164A:2914–2921.
31. Ishii A, Kang JQ, Schornak CC, et al. A de novo missense mutation of *GABRB2* causes early myoclonic encephalopathy. *J Med Genet* 2017;54:202–211.
32. Cogliati F, Giorgini V, Masciadri M, et al. Pathogenic variants in *STXBP1* and in genes for GABA_A receptor subunits cause atypical Rett/Rett-like phenotypes. *Int J Mol Sci* 2019;20:3621.
33. Baldrige D, Heeley J, Vineyard M, et al. The exome clinic and the role of medical genetics expertise in the interpretation of exome sequencing results. *Genet Med* 2017;19:1040–1048.
34. Yang Y, Xiangwei W, Zhang X, et al. Phenotypic spectrum of patients with *GABRB2* variants: from mild febrile seizures to severe epileptic encephalopathy. *Dev Med Child Neurol* 2020;62:1213–1220.
35. Nishikawa A, Otani Y, Ito S, et al. A de novo *GABRB2* variant associated with myoclonic status epilepticus and rhythmic high-amplitude delta with superimposed (poly) spikes (RHADS). *Epileptic Disord* 2020;22:476–481.
36. Yang Y, Zhang YH, Chen JY, et al. Clinical features of epilepsies associated with *GABRB2* variants [in Chinese]. *Zhonghua Er Ke Za Zhi* 2019;57:532–537.
37. Sobreira N, Schiettecatte F, Valle D, Hamosh A. GeneMatcher: a matching tool for connecting investigators with an interest in the same gene. *Hum Mutat* 2015;36:928–930.
38. Scheffer IE, Berkovic S, Capovilla G, et al. ILAE classification of the epilepsies: position paper of the ILAE Commission for Classification and Terminology. *Epilepsia* 2017;58:512–521.
39. Kwan P, Arzimanoglou A, Berg AT, et al. Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. *Epilepsia* 2010;51:1069–1077.
40. Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. *Genet Med* 2015;17:405–424.
41. Karczewski KJ, Francioli LC, Tiao G, et al. The mutational constraint spectrum quantified from variation in 141,456 humans. *Nature* 2020;581:434–443.
42. Kelly M, Park M, Mihalek I, et al. Spectrum of neurodevelopmental disease associated with the *GNAO1* guanosine triphosphate-binding region. *Epilepsia* 2019;60:406–418.
43. Olson HE, Poduri A, Pearl PL. Genetic forms of epilepsies and other paroxysmal disorders. *Semin Neurol* 2014;34:266–279.
44. Carecchio M, Mencacci NE. Emerging monogenic complex hyperkinetic disorders. *Curr Neurol Neurosci Rep* 2017;17:97.
45. Janve VS, Hernandez CC, Verdier KM, et al. Epileptic encephalopathy de novo *GABRB* mutations impair γ -aminobutyric acid type A receptor function. *Ann Neurol* 2016;79:806–825.
46. Shi YW, Zhang Q, Cai K, et al. Synaptic clustering differences due to different *GABRB3* mutations cause variable epilepsy syndromes. *Brain* 2019;142:3028–3044.
47. Reid CA, Kim T, Phillips AM, et al. Multiple molecular mechanisms for a single GABAA mutation in epilepsy. *Neurology* 2013;80:1003–1008.
48. Zhu S, Noviello CM, Teng J, et al. Structure of a human synaptic GABAA receptor. *Nature* 2018;559:67–72.
49. Wiel L, Baakman C, Gilissen D, et al. MetaDome: pathogenicity analysis of genetic variants through aggregation of homologous human protein domains. *Hum Mutat* 2019;40:1030–1038.